Vancomycin and oritavancin have different modes of action in Enterococcus faecium
about
Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killingNatural product disaccharide engineering through tandem glycosyltransferase catalysis reversibility and neoglycosylationOritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive InfectionsProfile of oritavancin and its potential in the treatment of acute bacterial skin structure infectionsManagement of multidrug-resistant enterococcal infectionsAntibiotics in the clinical pipeline at the end of 2015.Host-guest chemistry of the peptidoglycanStructural variations of the cell wall precursor lipid II and their influence on binding and activity of the lipoglycopeptide antibiotic oritavancin.Peptidoglycan architecture of Gram-positive bacteria by solid-state NMR.Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial.Further insights into the mode of action of the lipoglycopeptide telavancin through global gene expression studies.Bacterial cell wall composition and the influence of antibiotics by cell-wall and whole-cell NMR.Locations of the hydrophobic side chains of lipoglycopeptides bound to the peptidoglycan of Staphylococcus aureusProbing the biology of natural products: molecular editing by diverted total synthesis.The cell wall architecture of Enterococcus faecium: from resistance to pathogenesis.Glycopeptide antibiotics: back to the future.Therapeutic options for vancomycin-resistant enterococcal bacteremia.Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections.Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.Targeting bactoprenol-coupled cell envelope precursors.Characterization of the tertiary structure of the peptidoglycan of Enterococcus faecalis.Frequency-selective REDOR and spin-diffusion relays in uniformly labeled whole cells.Developments in Glycopeptide Antibiotics.Peptidoglycan Compositional Analysis of Enterococcus faecalis Biofilm by Stable Isotope Labeling by Amino Acids in a Bacterial Culture.Desleucyl-Oritavancin with a Damaged d-Ala-d-Ala Binding Site Inhibits the Transpeptidation Step of Cell-Wall Biosynthesis in Whole Cells of Staphylococcus aureus.Hidden Mode of Action of Glycopeptide Antibiotics: Inhibition of Wall Teichoic Acid Biosynthesis.
P2860
Q24606291-D0345F53-EF26-44CD-A6AB-7A35C45D1695Q24618494-2DF7F4AF-CF85-40BD-B597-3A26DB8D5E6AQ26772897-F062AF5B-D3CB-401C-BFCB-64FC9BFD0803Q26799701-6F3C9E54-D496-4AEC-B832-522DEA1CE908Q28285907-09EDA97B-A453-4BF8-B28C-6081A6229287Q30249262-B4E1F581-257D-4F25-9E03-56D47B9B64DAQ34013593-0A1DBE47-FF41-4C5F-80BD-3BD9D521D3C0Q34448260-29244F27-8B98-4161-A355-72E661E4EAB7Q34647068-2D1EC50B-BA6D-4226-B85B-C51C094B0603Q35065786-DA2D1BFD-4654-4E4B-AC9D-228059557E36Q36018648-FEBF4F0A-17A1-47BA-8072-2763BF111D07Q36247118-3DCC7DA3-CE37-4D61-8765-54141E20E310Q37185364-626870E8-21B5-4CF2-896E-514F62AED797Q37809500-0D318BBD-1E32-47B4-8802-996BBA7C406EQ38125495-A7961887-8679-4DB8-B9D2-C0D193E77026Q38239460-4EA3F4CE-D3BC-4F9C-8AD6-90CF21400102Q38347869-B8595286-DEB0-439F-8FF6-01BF1B087005Q38615330-CB4F6A54-49DD-4711-B1A2-9C5F9688E1AAQ38646905-F4D20BFF-94F7-47B4-9EF0-14982413DF43Q38919751-1E363D2B-F696-40FA-AEDB-8E8A12CF9E5AQ40103359-BCBB3ED2-3C1B-442D-A7BB-72D646E58C3BQ40401600-0BA55D34-A03B-40BF-9D1D-CF8006320AA5Q47715119-66049CC5-EA0C-4F0E-83EC-FDC49DFD409CQ48169079-F80F631C-501B-40F2-B5E9-C51A5D6F363AQ48213349-A5AFC9E7-2F75-4F09-9FDB-4E9C71B2EFBCQ48336817-163F9DBF-2DEF-4664-A00B-9E1BD6A38DA7
P2860
Vancomycin and oritavancin have different modes of action in Enterococcus faecium
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Vancomycin and oritavancin have different modes of action in Enterococcus faecium
@en
Vancomycin and oritavancin have different modes of action in Enterococcus faecium.
@nl
type
label
Vancomycin and oritavancin have different modes of action in Enterococcus faecium
@en
Vancomycin and oritavancin have different modes of action in Enterococcus faecium.
@nl
prefLabel
Vancomycin and oritavancin have different modes of action in Enterococcus faecium
@en
Vancomycin and oritavancin have different modes of action in Enterococcus faecium.
@nl
P2093
P2860
P1476
Vancomycin and oritavancin have different modes of action in Enterococcus faecium
@en
P2093
Adel Rafai Far
Evelyne Dietrich
Gary J Patti
Jacob Schaefer
Kelly S E Tanaka
Sung Joon Kim
Thomas R Parr
Tsyr-Yan Yu
P2860
P304
P356
10.1016/J.JMB.2009.06.064
P407
P577
2009-07-01T00:00:00Z